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Gastric Electrical Stimulation: A Novel Treatment
for Gastroparesis
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ABSTRACT
Presented herein is a case report of a laparoscopic gastric
electrical stimulator implantation for drug-refractory gas-
troparesis. Technical aspects of the procedure, as well as
a review of the existing literature, are discussed. Gastric
electrical stimulation offers a new alternative for the treat-
ment of drug-refractory gastroparesis.
Key Words: Gastroparesis, Gastric electrical stimulation,
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INTRODUCTION
Gastroparesis is a debilitating condition characterized by
delayed emptying of the stomach. Up to 36% of gastropa-
resis is of idiopathic origin, and 29% of diabetic origin.1
The hallmark of gastroparesis is early satiety, which may
progress to intractable nausea and vomiting. As a result of
these chronic symptoms, patients may have difficulty
meeting their nutritional and caloric needs. Dehydration,
weight loss, electrolyte imbalances, along with a deterio-
rating quality of life may ensue. In conjunction with di-
etary modifications, medical treatment includes the use of
prokinetic drugs. However, a majority of patients are in-
tolerant to these medications.
2 Many patients require en-
teral and parenteral nutrition support. The development
of a gastric electrical stimulation device has been associ-
ated with improvements in symptoms and an overall de-
creased cost of management of gastroparesis patients.
3
Approved by the FDA in March 2000, electrical stimulation
offers a promising therapy for gastroparesis refractory to
medical treatment. A technique of laparoscopic stimulator
implantation has yet to be described.
CASE REPORT
A 48-year-old Caucasian male with a history of hyperten-
sion and poorly controlled type II diabetes mellitus pre-
sented with 4 months of early satiety, epigastric pain,
heartburn, nausea, and daily emesis. An upper gastroin-
testinal endoscopy did not reveal any anatomic abnormal-
ities. Scintigraphy demonstrated greater than 50% gastric
content retention after 2 hours (Figure 1). Neither dietary
changes nor Metoclopromide administration provided
symptomatic relief. A diagnosis of drug-refractory diabetic
gastroparesis was made and a laparoscopic gastric elec-
trical stimulator implantation was planned.
The procedure requires 4 ports (Figure 2). Ten-mm ports
are placed in the left upper quadrant (lateral gastric re-
traction) and umbilicus (camera) and 5-mm ports (work-
ing ports) are placed in the left lower and right upper
quadrants. The surgeon stands on the patient’s right side.
The pylorus is identified, and a ruler is used to identify a
point 10 cm proximal to it along the greater curvature,
which is in the region of the pacemaker area. Marks are
made with electrocautery 1 cm apart on the gastric serosa.
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CASE REPORTThe lead is prepared by tying 2 silk sutures to its anchor.
After the lead is inserted through the left upper quadrant
port, the Prolene suture, which comes attached to the
electrode, is placed through the seromuscular layers of the
stomach. An upper gastrointestinal endoscopy assures
that the gastric mucosa has not been violated. The Prolene
suture is used to pull the electrode into the gastric mus-
cularis propria. The electrode is secured to the gastric wall
by using the silk suture, which had been previously tied to
the anchor with the intracorporeal knot tying technique.
The above procedure is repeated for a second lead with its
electrode placed 1cm from the first.
The leads are brought out through the left upper quadrant
port. An external programming device is used to confirm
that the impedance between the 2 electrodes is between
200 and 800 Ohms. The electrodes are then further se-
cured by placing a disc and 2 clips on the Prolene suture
adjacent to the electrode (Figure 3).
An abdominal wall subcutaneous pocket is made for the
stimulator 4 fingerbreadths below the left inferior costal
margin. The leads are tunneled from the left upper quad-
rant port site to the subcutaneous pocket, where they are
connected to the stimulator. Two sutures are used to
secure the stimulator to the abdominal wall fascia. The
pocket is closed in layers, and the stimulator parameters
are set by using the external programming device. The
voltage is calculated by multiplying the measured imped-
ance by a current of 5 mA. The other parameters include
a frequency of 14 Hz, a pulse width of 330 s and a
cycling time of 0.1 seconds on and 5 seconds off.
One month following surgery, the patient no longer re-
quired Metoclopramide. Two months later, he was symp-
tom free, on an unrestricted diet with significantly im-
proved glycemic control, and hemoglobin A1C within the
normal range. At 6 months following surgery, a gastric
scintigraphy demonstrated a normal pattern of gastric
emptying with 22% gastric content retention at 2 hours
(Figure 4).
DISCUSSION
Patients with complaints of early satiety, abdominal pain,
bloating, heartburn, nausea, and vomiting may be sus-
pected of having gastroparesis.
4 Persons with diabetes are
especially susceptible to gastroparesis as long-standing
hyperglycemia can lead to a vagal neuropathy.
Diabetics can become trapped in a downward spiral as
their irregular food intake and absorption contributes to
poor glycemic control, which in turn can exacerbate gas-
Figure 1. Gastric scintigraphy demonstrating a delayed pattern
of emptying, with greater than 50% gastric retention at 2 hours.
Figure 2. Port placement for laparoscopic stimulator implanta-
tion.
Figure 3. The electrode is secured by suturing the anchor to the
stomach wall proximally, and placing a disc and 2 clips on the
Prolene suture distally.
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tes or prior gastric surgery involving vagotomy, have not
been identified, patients are classified as having idiopathic
gastroparesis.
Contrast radiology or upper gastrointestinal endoscopy
studies are essential to rule out such conditions as gastric
outlet obstruction, but the most definitive test for a diag-
nosis of gastroparesis is gastric scintigraphy. Many con-
sider the test positive if the time at which 50% of the
technetium 99m-labeled test meal is eliminated from the
stomach (T1/2) is greater than 120 minutes after ingestion.
A T1/2 of 90 to 120 minutes is considered borderline for
gastroparesis. Greater than 10% retention after 4 hours is
also considered a positive test for delayed emptying.
5
Lack of gastric scintigraphy standardization among differ-
ent institutions makes interpretation of this test problem-
atic. Just as no consensus exists as to what constitutes a
positive test for delayed emptying, inconsistency exists
regarding the content of the radiolabeled meal.
Once the diagnosis of gastroparesis has been established,
a prokinetic therapy consisting of Cisapride, Domperi-
done, Erythromycin, or Metaclopromide may be offered.
However only Erythromycin and Metaclopromide are
commercially available in the United States, and up to 50%
to 75% do not respond or tolerate them.
2 For drug-refrac-
tory gastroparesis, traditional surgical approaches have
included decompressive gastrostomy and feeding jejunos-
tomy tube placement.
6 More invasive measures have con-
sisted of pyloroplasty and anterectomy, and in some in-
stances subtotal gastrectomy.
Many animal and human studies have been conducted in
an attempt to show the efficacy of electrical stimulation in
the treatment of gastroparesis. Encouraging results have
been reported with the use of a high-frequency, low-
energy gastric electric stimulator, which is attached to 2
leads implanted into the gastric muscularis propria.
7 The
device was developed by Medtronic, Inc. (Minneapolis,
MN, USA) and is marketed under the name Enterra Ther-
apy.
Results from a randomized, double-blinded crossover
multicenter trial of electrical stimulator implantation in-
volving 33 drug-refractory gastroparesis patients from the
US, Canada, and Europe demonstrated a decrease in
weekly vomiting frequency by greater than half in 70% of
the idiopathic and 77% of the diabetic patients.
7 A4 %
complication rate was observed including device infection
and lead displacement.7 Further, 14 patients in a prospec-
tive study of gastric electrical stimulation had a feeding
jejunostomy tube in place at the time of surgery. After 6
months, 11 of the 14 patients were sufficiently comfort-
able and stable with oral nutrition that their enteral access
could be removed.8 The number of hospital days per year
for patients with the gastric stimulator was cut by over 20
days. Patients with the gastric stimulator also have a de-
crease in utilization of outpatient health care resources.
3
CONCLUSION
Gastroparesis can be an incapacitating condition for many
patients. Although medical therapy should first be at-
tempted, it often is not successful. Gastric electrical stim-
ulation is a viable alternative. Laparoscopic implantation
confers the recognized advantages of a minimally invasive
approach.
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